Loading
Led ECHELON-1, which replaced bleomycin with brentuximab vedotin in first-line advanced Hodgkin lymphoma.
Joseph Connors was principal investigator of ECHELON-1, the trial showing brentuximab vedotin plus AVD improves progression-free and later overall survival compared with ABVD in advanced Hodgkin lymphoma, the first change to first-line therapy in decades. He built the BC Cancer lymphoid cancer database and population-based treatment guidelines that document real-world outcomes across all lymphomas.
Shares ECHELON-1, Brentuximab vedotin, Hodgkin lymphoma.
Shares Brentuximab vedotin, Antibody-drug conjugate (ADC) and the tag adc.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares BC Cancer, Antibody-drug conjugate (ADC) and the tag canada.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC) and the tag hodgkin.
Shares BC Cancer and the tag canada.
Shares Brentuximab vedotin, Hodgkin lymphoma, Antibody-drug conjugate (ADC).
Shares ECHELON-1, ECHELON-1: brentuximab vedotin replacing bleomycin in first-line chemotherapy for advanced Hodgkin lymphoma, Brentuximab vedotin, Hodgkin lymphoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/